- Policy
- Court controversy, the price of Synovian reduction postponed
- by Kim, Jung-Ju Dec 12, 2019 06:31am
- LG Chemicals dissatisfied with the drop in insurance prices, and the price of 3 ml of Synovian (BDDE cross-linked sodium hyaluronate gel), which is fighting a legal battle with the government, is being provisionally maintained. The trial is in progress, and the court has limited the time limit from the date of the sentence to 30 days. T
- Policy
- 5 years after the drug patent linkage system
- by Lee, Tak-Sun Dec 12, 2019 06:30am
- "There are many cases where overseas pharmaceutical companies have succeeded in using the US-licensed patent linkage system. But Korean pharmaceutical companies haven't even tried it. It's time to think about why they are not using the system". More than five years have passed since the introduction of Korean licensed patent linkage system
- Policy
- 10 new rare diseases applied with special case from 2020
- by Kim, Jung-Ju Dec 11, 2019 10:20pm
- Special case insurance benefit would be applied on ten new rare diseases including adult-onset Stills disease and Kienbock’s disease from next year. Korean Ministry of Health and Welfare (MOHW) issued a revised notice on Tuesday of ‘Standard on Special Case Insurance Benefit for Individual Copayment’ reflecting the changes. The specia
- Policy
- Kolon wins approval on inhaled schizophrenia treatment
- by Lee, Tak-Sun Dec 11, 2019 06:38am
- An orally inhaled medicine for treating agitation associated with schizophrenia is to be released in Korean market for the first time. The public’s interest is heightened by the news as inhalation powder has higher speed of body absorption and delivers effect in the shortest time. , Korean Ministry of Food and Drug Safety (MFDS) on Dec.
- Policy
- What should Metformin do?
- by Lee, Tak-Sun Dec 9, 2019 06:27am
- The MFDS, which has undergone a series of Ranitidine and Nizatidine events, has ordered companies to assess the likelihood of impurity on all synthetic drug substances. Of these, raw materials and finished products with high potential for impurity detection should be tested immediately and reported to the MFDS if abnormal quantities are detec
- Policy
- Investigation of raw materials for Metformin in Singapore
- by Kim, Jin-Gu Dec 9, 2019 06:27am
- The three Metformin products recovered from Singapore have yet to be imported in Korea. The Singapore Ministry of Health (HSA) recently surveyed 46 locally Metformin products and recovered three of them. N-nitrosodimethylamine (NDMA) was detected above the daily allowance (96 nanograms), explains the HSA. Two controversial companies are Gl
- Policy
- Reevaluation in follow-up again? VS doublecheck needed
- by Kim, Jung-Ju Dec 6, 2019 10:34am
- In the trend of reinforcing health insurance coverage, the policy of strengthening after-market insurance policy, which the government intends to strengthen as part of rational fiscal expenditure, is evaluated in various ways as well as the depth and breadth of coverage. The 'preparation criteria and methods for the evaluation of drugs', whic
- Policy
- Introduction-development-turn, and the price reduction
- by Kim, Jung-Ju Dec 6, 2019 09:46am
- The pharmaceutical industry's reaction to the ambitious post-evaluation of the high-priced drugs, ambitiously issued by the government and insurance authorities, is cold. The pharmaceutical community understood the big direction of follow-up of drugs for rational fiscal expenditure, coupled with enhanced security. At the same time, it is a ma
- Policy
- Investing KRW 4 tn fostering Biohealth as ‘Post-semiconduct
- by Kang, Shin-Kook Dec 6, 2019 09:43am
- Until 2025, the Korean government is to assertively invest four trillion won on fostering biohealth industry as a ‘post-semiconductor industry.’ On Dec. 4, Deputy Prime Minister Hong Nam-ki led the fifth Innovative Growth Strategy meeting and the 28th Economic Ministerial meeting and discussed about next generation innovative growth engine
- Policy
- “Providing as much clinical information for patients”
- by Lee, Tak-Sun Dec 5, 2019 06:23am
- Since the end of last October, the Korean Ministry of Food and Drug Safety (MFDS) has expanded scope of information on approved investigation new drug’s (IND) protocol uploaded on its website. Previously, only the names of clinical trial, sponsoring client, IND, targeting disease and clinical trial institute were publicly disclosed, but
